Sinclair Launches Préime DermaFacial at IMCAS 2022

Sinclair, (www.sinclair.com) a global aesthetics company headquartered in London and fully owned subsidiary of Huadong Medicine Corporation Limited announces the launch of Préime DermaFacial at the IMCAS world congress in Paris.

Préime DermaFacial is a smart device, powered by Internet of Things (IoT) technology, designed to ensure consistent results and excellent patient outcomes. This state-of-the-art system offers a completely new approach in performing treatments, by delivering actual data to the aesthetic
providers, allowing users to understand, examine and constantly improve their own methods and practices.

The Préime DermaFacial is a pioneer in combination therapy offering five powerful technologies, allowing the curation of personalised treatments. It has been designed by skincare experts, for skincare experts. Focusing on efficacy, limitless treatment combinations and ease of use. Préime
DermaFacial is the primary skincare platform for clinics, aesthetic centres and medspas.

This is another milestone for the company that acquired Cocoon Medical in April 2021 and, in February 2022, added the exciting range of energy-based devices from Viora to its portfolio. Sinclair now has a wide range of products, both injectable fillers and energy-based devices, offering patients a wide variety of aesthetic procedures. The company is on a mission to transform customer confidence with patient safety and satisfaction at the core of everything we do.

Miguel Pardos, CEO of Sinclair commented: “We are delighted to be exhibiting at the IMCAS congress this year and I am looking forward to welcoming our customers and business partners to our stand where they will be able to see our new brand design, our products and meet the global team present.

To see the new brand visit www.sinclair.com; www.linkedin.com; and on Instagram @sinclair.global
About Huadong Medicine Co., Ltd.

About Huadong Medicine Co., Ltd.
HMC(SZ.000963), listed in 1999, is one of the top manufacturers and distributors of pharmaceutical and medical products in China, where it has over 12,000 employees and generated approximately $5.1 billion of revenue in the financial year ended 31 December 2021. Over the past five years, HMC has established a leading aesthetics business in China, offering a variety of fillers. HMC is an affiliate of China Grand Enterprise Inc. (CGE), an investment group headquartered in Beijing. CGE has four business sectors: pharmaceuticals and healthcare, commodities trading, real estate investment and financial services, among which, pharmaceuticals and healthcare sector is the core business. CGE is ranked in the top five enterprises in the Chinese Pharmaceutical industry and manages over 60 pharmaceutical subsidiary companies, HMC is the largest one.

About Sinclair
Sinclair is an international company operating in the fast growth, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies in both the injectable and EBD segments. Both divisions are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. Sinclair is planning entry to multiple new geographic markets and line extension launches over the next few years. The Group has an established sales and marketing presence in the EU markets, Brazil, Mexico, Colombia, UAE, Hong Kong and South Korea and a network of international distributors.

For more information, visit www.sinclair.com

Media Contacts:
Emilie Croissant, Lee Anne Evans, Dave Baldwin
Email: info@sinclair.com
Tel: +44 (0) 20 7467 6920